ACADIA Pharmaceuticals Inc.
General ticker "ACAD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.0B (TTM average)
ACADIA Pharmaceuticals Inc. follows the US Stock Market performance with the rate: 32.7%.
Estimated limits based on current volatility of 1.5%: low 28.69$, high 29.50$
Factors to consider:
- Total employees count: 798 (+22.0%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Commercialization failure, Clinical trial failure, Regulatory and compliance, Supply chain disruptions, Geopolitical risks
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [21.36$, 35.73$]
- 2026-12-31 to 2027-12-31 estimated range: [23.01$, 38.09$]
Financial Metrics affecting the ACAD estimates:
- Positive: with PPE of 12.0 at the end of fiscal year the price was neutral
- Positive: 7.80 < Operating profit margin, % of 9.78
- Positive: Return on assets ratio (scaled to [-100,100]) of 20 > 6.06
- Positive: -14.39 < Investing cash flow per share per price, % of -6.51
- Positive: Shareholder equity ratio, % of 78.47 > 63.63
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: 0.28 < Operating cash flow per share per price, % of 2.36
Short-term ACAD quotes
Long-term ACAD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $726.44MM | $957.80MM | $1,071.51MM |
| Operating Expenses | $799.82MM | $727.00MM | $966.69MM |
| Operating Income | $-73.38MM | $230.79MM | $104.81MM |
| Non-Operating Income | $22.34MM | $27.28MM | $34.09MM |
| R&D Expense | $351.62MM | $303.25MM | $328.80MM |
| Income(Loss) | $-51.04MM | $258.07MM | $138.90MM |
| Taxes | $10.25MM | $31.62MM | $-252.10MM |
| Net Income(Loss)* | $-61.29MM | $226.45MM | $391.00MM |
| Stockholders Equity | $431.75MM | $732.79MM | $1,227.39MM |
| Inventory | $35.82MM | $21.95MM | $34.67MM |
| Assets | $748.96MM | $1,187.76MM | $1,564.19MM |
| Operating Cash Flow | $16.70MM | $157.72MM | $109.84MM |
| Capital expenditure | $40.05MM | $0.52MM | $4.69MM |
| Investing Cash Flow | $32.00MM | $-30.54MM | $-302.56MM |
| Financing Cash Flow | $25.13MM | $6.84MM | $49.88MM |
| Earnings Per Share** | $-0.37 | $1.37 | $2.31 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.